FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents


Drug, Bio-affecting And Body Treating Compositions > Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material > Binds Eukaryotic Cell Or Component Thereof Or Substance Produced By Said Eukaryotic Cell (e.g., Honey, Etc.)

Binds Eukaryotic Cell Or Component Thereof Or Substance Produced By Said Eukaryotic Cell (e.g., Honey, Etc.)

Binds Eukaryotic Cell Or Component Thereof Or Substance Produced By Said Eukaryotic Cell (e.g., Honey, Etc.) patent applications listed include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

04/10/14 - 20140099329 - Treatment of diseases and disorders using self-renewing colony forming cells cultured and expanded in vitro
The present invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult...

04/10/14 - 20140099330 - Method and system for treating biological tissue
A tissue prosthesis comprising a support structure having at least one surface, the support structure comprising a base material, the support structure further including an extracellular matrix (ECM) composition having at least one ECM material from a mammalian tissue source. The tissue prosthesis induces modulated healing of damaged biological tissue...

04/03/14 - 20140093519 - Methods for pancreatic tissue regeneration
Disclosed are methods of expanding populations of pancreatic cells or inducing the generation of pancreatic progenitor cells in a subject or in culture using a therapeutically effective amount of a TWEAK receptor agonist. These methods may be used to treat diseases or conditions where enhancement of pancreatic progenitor cells for...

04/03/14 - 20140093520 - Vegf-d/vegfr2/3-mediated regulation of dendrites
The present invention relates to methods for modulating, i.e. increasing or decreasing, the length and/or the complexity of the dendrites of a neuronal cell by influencing the amount of vascular endothelial growth factor D (VEGFD)-related signaling. The present invention further relates to methods for treating age- and/or disease-related cognitive dysfunctions,...

03/27/14 - 20140086937 - Immunological control of beta-amyloid levels in vivo
Disclosed herein are compositions and methods useful for controlling β-amyloid levels. In particular, the instant invention relates to an antibody that catalyzes hydrolysis of β-amyloid at a predetermined amide linkage are provided. The present invention also provides a vectorized antibody that is capable of crossing the blood brain barrier and...

03/13/14 - 20140072578 - Anti-cd100 neutralizing antibodies and methods of using the same
Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD 100 monoclonal antibodies have been developed to neutralize CD100....

03/13/14 - 20140072579 - Methods and means for the production of ig-like molecules
The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided....

03/13/14 - 20140072580 - Novel targets for treatment of hypercholesterolemia
In certain embodiments this invention this invention pertains to the discovery that inhibition of myosin light chain interacting protein (Mylip) can mitigate one or more symptoms of hypercholesterolemia. Methods of treating hypercholesterolemia and methods of screening for agents to treat hypercholesterolemia are provided....

03/13/14 - 20140072581 - Immunoglobulin constructs comprising selective pairing of the light and heavy chains
Disclosed herein is an isolated immunoglobulin construct comprising a first monomeric polypeptide comprising a first single chain Fv polypeptide connected to a first constant domain polypeptide; and a second monomeric polypeptide comprising a second single chain Fv polypeptide, connected to a second constant domain polypeptide; each said constant domain polypeptide...

03/13/14 - 20140072582 - Molecules with antigen binding and polyvalent fc gamma receptor binding activity
The current invention involves biologically active proteins termed stradobodies. The stradobodies have two or more domains that create stradobody multimers. The stradobodies have both antigen-binding capacity and the ability to bind Fc receptors (FcR), and are useful in the treatment and prevention of disease....

03/13/14 - 20140072583 - Methods for treating atopic dermatitis by administering an il-4r antagonist
The present invention provides methods for treating atopic dermatitis (AD). Also provided are methods for improving one or more AD-associated parameter(s), and methods for decreasing the level of at least one AD-associated biomarker in a subject in need thereof. The methods of the present invention comprise administering to a subject...

03/06/14 - 20140065167 - Human igm antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
Antibodies, particularly human antibodies, are disclosed having activity in treatment of demyelinating diseases and diseases of the central nervous system. Neuromodulatory agents are provided comprising a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, and...

03/06/14 - 20140065168 - Anti-kit antibodies and uses thereof
Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit...

02/27/14 - 20140056915 - High affinity antibody antagonists of interleukin-13 receptor alpha 1
High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody...

02/27/14 - 20140056916 - Aldosterone induced vascular elastin production
Compositions and methods for inducing the deposition of elastin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein....

02/27/14 - 20140056917 - Fty720 increases cd74 expression and sensitizes cancer cells to anti-cd74 antibody-mediated cell death
Disclosed herein are methods and compositions comprising fingolimod and anti-CD74 antibodies or fragments thereof. In preferred embodiments, the fingolimod increases the expression of CD74 in target cells and increases the sensitivity of the cells to the cytotoxic effects of the anti-CD74 antibodies. The compositions and methods are of use to...

02/27/14 - 20140056918 - Oscar antagonists
The present invention relates to antagonistic OSCAR ligands. The present invention furthermore relates to use of such ligands....

02/27/14 - 20140056919 - Methods and compositions for treating inflammatory conditions
The present invention is directed to methods of treating an inflammatory condition in a patient. This method includes providing a therapeutic agent that is a vascular endothelial growth factor receptor-3 (VEGFR-3) agonist or a nucleic acid molecule encoding a VEGFR-3 agonist. The present invention is further directed to pharmaceutical compositions...

02/20/14 - 20140050742 - Methods and compositions for modulating lymphangiogenesis, e.g., to treat transplant rejection, in a subject
Methods of modulating the occurrence of lymphangiogenesis in a subject are provided. In some instances, the method is a method of treating transplant rejection in the subject. Aspects of the methods include administering to the subject an effective amount of: a first antagonist for a tyrosine kinase receptor and a...

02/13/14 - 20140044733 - Antibody based reagent that specifically recognizes toxic oligomeric form of beta-amyloid
The invention relates to antibodies, antibody fragments and binding agents that specifically recognizes oligomeric Aβ that is resistant to denaturation by SDS but does not bind monomeric, fibrillar or other oligomeric forms of Aβ that are generated in vitro....

02/13/14 - 20140044734 - Method for treating liver inflammation, fibrosis and non-alcoholic steatohepatitis
The invention is in the field of prevention and medical treatment of liver diseases, in particular non-alcoholic steatohepatitis (NASH). The invention provides means and methods for the treatment of hepatic inflammation, fibrosis and more in particular NASH. More in particular, the invention provides a composition capable of raising anti-oxLDL antibodies...

02/13/14 - 20140044735 - Methods to characterize patients suffering from hemolysis
The present invention relates to methods for determining the risk of severe complications in hemolytic diseases. The present invention relates to a method for determining whether a patient suffering from sickle cell disease is at risk for a vaso-occlusive crisis comprising the steps consisting of i) determining the level of...

02/13/14 - 20140044736 - Procollagen carboxy-terminal propeptides as a target and treatment for angiogenesis related diseases
The present invention relates to the field of angiogenesis. More specifically, the present invention provides methods and compositions for modulating angiogenesis. In a specific embodiment, a method for modulating a blood vessel in a subject in need thereof comprising contacting a cell of the subject with a procollagen carboxy-terminal propeptide,...

02/13/14 - 20140044737 - Rbp4 in insulin sensitivity/resistance, diabetes, and obesity
Methods for screening molecules that modulate the activity of Retinol Binding Protein 4 (RBP4) and their use in treatment of insulin resistance are described. Also described are methods of diagnosing insulin resistance and related conditions by detecting modulation of RBP4 activity....

02/13/14 - 20140044738 - Antibodies and other molecules that bind b7-h1 and pd-1
The present invention relates to antibodies and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to B7-H1 or PD-1. In some embodiments such molecules are additionally capable of modulating the ability of B7-H1 or B7-DC to bind to PD-1 or are capable of affecting the...

02/06/14 - 20140037652 - Detection and treatment of polycystic kidney disease
Compositions useful for examining the PKD1 gene are provided. In addition, methods for detecting mutations of the PKD1 gene, which can be associated with autosomal dominant polycystic kidney disease in humans, are provided. Methods for diagnosing a mutant PKD1 gene sequence in a subject also are provided, as are methods...

02/06/14 - 20140037653 - Modulation of lrch4 activity and therapeutic application thereof
Disclosed herein are methods for altering cellular functions and processes by modulating the activity of Lrch4. Corresponding compositions that may be used in carrying out the described methods are also disclosed as are related methods of treatment for relevant diseases and physiological states....

01/30/14 - 20140030273 - Human antibodies and antibody-drug conjugates against cd74
Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed....

01/30/14 - 20140030274 - Amyloidosis target useful in methods of treatment and for screening of compounds
A method involves screening a candidate compound for activity in the treatment of a condition associated with formation of amyloid protein fibrils in a mammal, such as Alzheimer's disease. It is determined whether the trimer/monomer ratio of a chaperone protein is decreased in the presence of the candidate compound. The...

01/30/14 - 20140030275 - A-beta binding polypeptides
The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including...

01/23/14 - 20140023661 - Combination therapy
The present invention relates to a pharmaceutical combination comprising an alpha-isoform specific phosphatidylinositol 3-kinase inhibitor compound, such as (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide), or pharmaceutically acceptable salt thereof, and an IGF1R inhibitor (e.g., the IGF1R inhibitor ANTIBODY A, or a variant or derivative thereof), a pharmaceutical composition comprising such combination, methods...

01/23/14 - 20140023662 - Non-antagonistic egfr-binding molecules and immunoconjugates thereof
Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided....

01/16/14 - 20140017259 - Immunotherapy against erbb-3 receptor
The present invention describes methods and pharmaceutical compositions for the treatment of cancer in mammals, more particularly in human subjects. More specifically, the invention concerns anti-tumor vaccines based upon plasmid DNA and/or genetic vectors carrying a codon-usage optimized sequence and coding for a mutant form of the ErbB-3 receptor. Furthermore,...

01/16/14 - 20140017260 - Methods and materials for reducing bone loss
This document provides methods and materials involved in reducing bone loss. For example, methods and material for using one or more inhibitors of a Rorβ polypeptide to reduce bone loss are provided. In some cases, methods and material for using one or more inhibitors of a Rorβ polypeptide to treat...

01/16/14 - 20140017261 - Selection and treatment of subjects
The invention relates to methods of selecting a subject, and methods of treating the subject with an anti-VLA-1 antibody. In one embodiment the first therapeutic agent is a DMARD (Disease Modifying Antirheumatic Drug), such as gold salts; hydroxychloroquine; an antifolate, such as methotrexate; a pyrimidine synthesis inhibitor, such as leflunomide;...

01/09/14 - 20140010825 - Diagnostic and therapeutic potential of hla-e monospecific monoclonal igg antibodies directed against tumor cell surface and soluble hla-e
Provided herein are compositions comprising purified antibodies and fragments thereof that are specifically immunoreactive to only human leukocyte antigen E (HLA-E) but not to other HLA Ia and HLA-Ib alleles. Also provided are methods of their making and diagnostic and therapeutic applications. The monospecific HLA-E antibodies are highly specific and...

01/09/14 - 20140010826 - Use of dr6 and p75 antagonists to promote survival of cells of the nervous system
The present invention relates to Death Receptor-6 (DR6) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to be important for regulating apoptosis in cells of the nervous system. In addition, it has been discovered that p75 is a ligand for DR6....

01/09/14 - 20140010827 - Antibody formulations
Formulations of anti-VLA-1 antibodies are described....

01/02/14 - 20140004129 - Novel polypeptides involved in immune response
Polypeptides which comprise a receptor-ligand pair involved in T-cell activation are disclosed. Nucleic acid molecules encoding the polypeptides, and vectors and host cells for expressing the polypeptides are also disclosed. The polypeptides, or agonists and antagonists thereof, are used to treat T-cell mediated disorders....

01/02/14 - 20140004130 - Mia (melanoma inhibitory activity) inhibitors for detecting, preventing and curing vitiligo
Peptides, modified peptides and antibody or antibody fragment, which inhibit the activity of MIA (Melanoma Inhibitory Activity), for detecting, preventing and curing vitiligo are disclosed....

12/26/13 - 20130344087 - Combinations of anti-s1p antibodies and shpingolipid pathway inhibitors
Methods for administering combinations of compositions comprising anti-S1P antibodies or antibody fragments and modulators of sphingolipid metabolic pathway enzymes are described. Such methods allow aberrant or undesirable levels of S1P to be reduced in patients known or suspected to have a disease or disorder correlated with aberrant S1P levels, and...

12/26/13 - 20130344088 - Antibody formulation
Anti-BAFFR antibodies are formulated as liquid formulation comprising a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The aqueous pharmaceutical composition may include one or more sugars, a buffering agent, a surfactant, and/or a free amino acid....

12/26/13 - 20130344089 - Anti oligomer antibodies and uses thereof
The present invention relates to antibodies and antibody fragments specific for the toxic prefibrillar aggregates of amyloid-beta peptides, and uses thereof, for example in the diagnosis and treatment of amyloid diseases such as Alzheimer's disease and related disorders. The invention further provides methods for the identification of compounds potentially useful...

12/26/13 - 20130344090 - Antibodies against tissue factor pathway inhibitor (tfpi)
The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce clotting time in (a) human FVIII-deficient plasma and/or (b) human whole blood. Such antibodies have utility in the treatment of bleeding disorders and in the stimulation of blood clotting....

12/26/13 - 20130344091 - Compositions and methods for increasing muscle growth
This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse....

12/19/13 - 20130336990 - Enhancement of the action of anti-infective agents and of central and peripheral nervous system agents and transportation of nucleic acid substances
The invention provides a method of enhancing the action of a pharmaceutical agent selected from the group consisting of the anti-infective agents, the group comprising of the antimicrobial agents, the anthelmintic agents and the anti-ectoparasitic agents, but excluding coal tar solution and H1-antagonist antihistamines, and from the group consisting of...

12/19/13 - 20130336991 - Sp35 antibodies and uses thereof
Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of...

12/19/13 - 20130336992 - Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies....

12/12/13 - 20130330359 - Composition and method for the diagnosis and treatment of iron-related disorders
Provided herein are antibodies and methods of using the antibodies to treat, prevent, modulate, attenuate and diagnose iron-related disorders....

12/12/13 - 20130330360 - Antagonistic dr3 ligands
The present disclosure relates to treatment of inflammatory diseases. In particular, the present disclosure relates to antagonistic DR3 ligands useful for treating inflammatory diseases....

12/12/13 - 20130330361 - Composition comprising expression or activity regulators of akap12 for treating central nerve system diseases
The invention includes a pharmaceutical composition comprising an expression or activity regulator of AKAP12 (A-kinase anchoring protein 12) as the active ingredient. The compositions of the invention are useful for treating central nervous system diseases. The invention further includes a method of treating central nervous system diseases using a pharmaceutical...